ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the Company” or “RegeneRx”) announced today that the Company received a patent in Australia using thymosin beta 4 (Tß4) for the treatment of a broad array of gastrointestinal infections and disorders. The patent expires in 2023. RegeneRx has patents pending for this use in a number of countries, including the U.S.
